Retatrutide is Eli Lilly's triple agonist - one weekly injection that hits three receptors at once (GLP-1, GIP, glucagon)
[1] These results made tirzepatide the most effective approved obesity pharmacotherapy at the time of its launch
It exists solely to let your body adjust to the GLP-1 and GIP receptor activation that tirzepatide triggers
Metabolites 12:1 Hafiz R, Gandhi TK, Mishra S, Prasad A, Mahajan V, Di X, Natelson BH, Biswal BB (2022) Higher limbic and basal ganglia volumes in surviving covid-negative patients and the relations to fatigue
Biochim Biophys Acta Mol Basis Dis (2018) 1864(9 Pt B):281421
Risk of bias was assessed using Cochrane Collaboration criteria specifically evaluating sequence generation of allocation